STROBE Statement—Exploring Plasma Metabolomic Changes of Sepsis: A Clinical Matching Study Based on Gas Chromatography Mass Spectrometry

| Section/item | Item No | Recommendation | Reported on Page Number/Line Number | Reported on Section/ Paragraph |
|------------------------|------------|---|--|--------------------------------|
| Title and abstract | 1a | Identification as a clinical matching study in the title. | Page1/Line1-2 | Title/Paragraph1 |
| | 1b | Structured summary of trial design, objective, methods, results, and conclusions; for specific guidance | Page1/Line11-30 | Abstract/Paragraph1-4 |
| | | see CONSORT for Abstracts. | Page2/Line1-4 | |
| Introduction | | | | |
| Background/ rationale | 2 | Scientific background and explanation of sepsis and related biomarkers | Page3/Line2-24 | Introduction/Paragraph1-2 |
| Objectives | 3 | Specific objectives or hypotheses(metabolomics of sepsis) | Page3/Line25-34 | Introduction/Paragraph3 |
| Methods | | | | |
| Study design | 4 | Description of study design including approval from institution and volunteers. | Page4/Line3-16 | Methods/Paragraph1 |
| Setting | 5 | Settings, locations, periods, and control group of recruitment of the data were collected. | Page4/Line3-16 | Methods/Paragraph1 |
| Study size | 6 | How sample size was determined | Page4/Line7-10 | Methods/Paragraph1 |
| Participants | 7a | Matching criteria for participants | Page4/Line7-10 | Methods/Paragraph1 |
| | 7b | Sample preparation and labeling | Page4/Line13-24 | Methods/Paragraph2 |
| Variables | 8 | Flow chart of our study | Figure 1 | Figure 1 |
| Data sources/ | 9 | Gas chromatography-mass spectrometry analysis. | Page4/Line26-Page5/Line2 | Methods/Paragraph3 |
| measurement | | | | |
| Quantitative Variables | 10 | Eligibility criteria for each subgroup. | Page5/Line3-31 | Methods/Paragraph4-7 |
| Statistical methods | 11a | Statistical methods used to deconvolve the GC-MS spectra | Page5/Line33- Page6/Line4 | Methods/Paragraph8 |
| | 11b | Bias, data normalization. | Page6/Line4-6 | Methods/Paragraph8 |

| | 11c | Statistical methods used to compare groups for primary and subgroup analyses | Page6/Line6-22 | Methods/Paragraph8 |
|-------------------|-----|---|-----------------------------|--------------------------|
| Results | | | | . |
| Participants | 12 | For each group, the numbers of participants who provided by ICU and the Healthy Examination | Page6/Line28-30 | Results/Paragraph1 |
| | | Center, and were analyzed for the primary outcome. | Table 1 | Table 1 |
| Implementation of | 13 | To verify the model of results. | Page6/Line26-30 | Results/Paragraph1 |
| intervention | | | Figure 2 | Figure 2 |
| Descriptive and | 14a | For each group, the characteristics and comparative analysis of metabolites of sample. | Page7/Line3-26 | Results/Paragraph2 |
| outcome data | | | Figure 2 | Figure 2 |
| | 14b | For each group, the characteristics and comparative analysis of metabolic pathways of sample. | Page7/Line28-Page8/Line14 | Results/Paragraph3 |
| | | | Figure 3 | Figure 3 |
| Other analyses | 15 | Subgroup analysis (AKI, ARDS, SIMD, AHI) | Page8/Line15-Page9/Line31 | Results/Paragraph4-7 |
| | | | Table 2-5 | Table 2-5 |
| | | | Figure 4-7 | Figure 4-7 |
| Discussion | | | | |
| Interpretation | 16a | A cautious overall interpretation of results. | Page9/Line33-Page12/Line5 | Discussion/Paragraph1-4 |
| | 16b | A cautious overall interpretation of results about subgroup (AKI, ARDS, SIMD, AHI) | Page12/Line6-Page13/Line30 | Discussion/Paragraph5-10 |
| Limitations | 17 | Discuss limitations of the study both direction and magnitude of any potential bias | Page13/Line31-Page14/Line11 | Discussion/Paragraph10 |
| Generalisability | 18 | GC-MS analysis may as a detection tool for plasma metabolomics analysis of sepsis and related organ | Page14/Line11-14 | Discussion/Paragraph10 |
| | | dysfunction. | | |
| Key results | 19 | Summarise key results to study objectives | Page14/Line16-24 | Conclusions/Paragraph1 |

| Funding 20 Sources of funding and other support (e.g., supply of drugs); role of funders. | Page15/Line6-17 | Funding/Paragraph1 |
|---|-----------------|--------------------|
|---|-----------------|--------------------|

Note: This is an explanation and elaboration checklist discussing each checklist item, reported on page number/line number and reported on section/paragraph in main text. We strongly recommend reading it in conjunction with main text.

Article Information: http://dx.doi.org/10.21037/atm-20-3562

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.